Introduction
============

Hypopharyngeal squamous cell carcinoma (HPSCC) is a common type of head and neck cancer that is associated with a high invasiveness and a poor prognosis. Recently, surgical resection along with chemoradiation therapy have been indicated as a good modality for HPSCC treatment; however, the majority of patients with HPSCC have an unfavorable prognosis due to diagnosis at an advanced stage with the presence of distant metastasis and therefore, the opportunity for radical treatment is lost. It has been reported that the overall survival rate of patients with HPSCC is only 15--45% ([@b1-or-40-02-0647],[@b2-or-40-02-0647]). The etiological factors of HPSCC are unclear. A series of recent studies have described that smoking (active and passive), alcohol consumption and exposure to the human papilloma virus may be risk factors for the development of HPSCC ([@b3-or-40-02-0647]--[@b5-or-40-02-0647]).

The pathophysiological mechanisms of HPSCC are not yet well understood. Previous studies have demonstrated that ectopically expressed genes, microRNAs (miRNAs or miRs) and long non-coding RNAs were involved in the initiation, development and prognosis of HPSCC. Tumor necrosis factor receptor 1 (TNFR1) is a membranous receptor that anchors on the surface of the cell membrane, which belongs to the TNF receptor superfamily ([@b6-or-40-02-0647],[@b7-or-40-02-0647]). The upregulation of TNFR1 has been shown to be associated with clinical staging, T stage, cervical lymph node metastasis and histological grade in HPSCC ([@b8-or-40-02-0647]). The immunoglobulin heavy chain binding protein (BiP)/glucose-regulated protein 78 (GRP78) plays an important role in the endoplasmic reticulum stress and is known to be highly expressed in various human neoplasms. A decreased expression of GRP78/BiP has been reported to predict a poor overall survival and progression-free survival of patients with advanced HPSCC ([@b9-or-40-02-0647]). The downregulation of miR-140-5p has also been shown to be associated with tumor stage and lymph node metastasis, and the restoration of miR-140-5p inhibits cell migration and invasion in HPSCC by targeting ADAM metallopeptidase (ADAM10), which is involved in the Notch1 signaling pathway ([@b10-or-40-02-0647]). The expression of AB209630, a long non-coding RNA, has been shown to be markedly lower in HPSCC cell lines and tumor tissues compared with the normal cells and tissues, and functions as a tumor suppressor in HPSCC. A high expression of AB209630 significantly has been shown to inhibit the growth, metastasis and invasion of HSPCC *in vitro*, and a decreased expression of AB209630 predicts a poorer prognosis ([@b11-or-40-02-0647]). In addition, abnormal methylation is associated with tumorigenesis in HSPCC. The hypermethylation of G protein-coupled receptor kinase 6 (GRK6) has been observed in HPSCC tissues compared to the matched adjacent normal tissues. GRK6 is also associated with tumor invasion and TNM stage in HPSCC ([@b12-or-40-02-0647]).

HPSCC is a common malignancy with a poor prognosis. To the best of our knowledge, the expression profiling of mRNAs and miRNAs via RNA-sequencing has not yet been documented in HPSCC. In the present study, we used high-throughput RNA-sequencing to examine gene and miRNA expression and to investigate the functional significance of aberrantly expressed genes and miRNAs in HSPCC, with the aim of providing the groundwork for the elucidation of HPSCC tumorigenesis and potential biomarkers for the early diagnosis of HPSCC.

Materials and methods
=====================

### Patients and samples

A total of 3 patients diagnosed with HPSCC were enrolled in this study from the First People\'s Hospital of Jining from August, 2015 to January, 2016. The mean age of the 3 patients with HPSCC was 60.7 years (range, 56--64 years). All 3 patients with HPSCC patients with squamous cell carcinoma were male. All patients had lymph node metastasis tumor loci. Primary HPSCC tissues and adjacent normal tissues of patients were obtained through surgical resection. The TNM stage and tumor grade of the patients are presented in [Table I](#tI-or-40-02-0647){ref-type="table"}. The study was approved by the Ethics Committee of the First People\'s Hospital of Jining, and informed written consent was obtained from all patients. Primary tumors and adjacent normal tissues of patients with HPSCC were obtained based on the Declaration of Helsinki.

### Isolation of RNA

A total of 6 specimens from the 3 patients were used for RNA isolation using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer\'s instructions. RNA quality and quantity were assessed using the NanoDrop 2000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific) and Agilent 2100 bioanalyzer (Agilent Technologies GmbH, Waldron, Germany). The average RNA quantity for the specimens was 73.42 µg (0.84--174.98 µg) with RNA integrity number (RIN) values between 1.0 and 7.6.

### Library preparation and RNA sequencing

The Illumina TruSeq RNA Sample Prep kit (Illumina, Inc., San Diego, CA, USA) was used for the library preparation according to the manual. PolyT oligo-conjugated magnetic beads were used to enrich the RNA with polyA+ tail, followed by mRNA fragmentation, first strand cDNA synthesis, second strand cDNA synthesis and end repair. Subsequenlty, the product was ligated to Illumina TruSeq adaptors. Following PCR amplification, enriched cDNA libraries were sequenced using the Illumina HiSeq 2500 sequencing platform (Illumina).

### Data preprocessing

The raw data from high-throughput RNA-sequencing was translated into raw FASTQ sequence data by base calling. Raw RNA-sequencing data were filtered and trimmed using FASTx-Tool SeqPrep (<https://github.com/jstjohn/SeqPrep>) and Sickle (<https://github.com/najoshi/sickle>). Clean and trimmed FASTQ reads were aligned to the human hg19 genome by using TopHat (version 1.3.1; Center for Computational Biology, Johns Hopkins University, Baltimore, MD, USA) ([@b13-or-40-02-0647]). The aligned read files were then processed using Cufflinks version 1.2.1 software package (Trapnell Lab, Seattle, WA, USA) which assessed the abundance of genes ([@b14-or-40-02-0647]). Fragments per kilobase of transcript per million mapped reads (FPKM) was used to determine the transcription abundance of each gene.

### Differentially expressed genes (DEGs) and miRNAs

The DEGs between HPSCC tumor and adjacent normal tissues were carried out using paired t-tests and limma package in R ([@b15-or-40-02-0647]). The false discovery rate (FDR) was performed; multiple testing corrections of raw P-values were performed using the Benjamini and Hochberg method ([@b16-or-40-02-0647],[@b17-or-40-02-0647]). The genes with an FDR \<0.05 and abs (log~2~ fold change) \>1 were screened as DEGs. A two-way hierarchical clustering analysis was conducted to assess the similarity of gene expression patterns between samples, and the results were displayed in a heatmap using the 'pheatmap' package ([@b18-or-40-02-0647]). In addition, DEGseq (<http://bioconductor.org/packages/DEGseq/>) was applied to quantify the expression of miRNAs. miRNAs with P-value \<0.001 and abs (log~2~FC) \>2 were screened as differentially expressed miRNAs.

### Analysis of the miRNA target genes

Identifying the target genes of miRNAs is a key step towards studying the function of miRNAs in specific tissues and cells. In the present study, 6 miRNA-target prediction tools (DIANAmT, miRanda, miRDB, miRWalk, PICTAR5 and TargetScan) were applied to predict the target genes of differentially expressed miRNAs. The miRNA-targets that were predicted by \>4 algorithms or verified by experiment in the miRWalk database were identified. All miRNA-target pairs were obtained, which were not only predicted by algorithms (or verified by experiment), but also negatively associated in the expression level. The miRNA-target regulatory network was then constructed, which was visualized using Cytoscape ([@b19-or-40-02-0647]).

### Functional annotation of DEGs

The Gene Ontology (GO) function was used to elucidate the biological function of DEGs in biological process, molecular function and cellular component using the GeneCodis 3 online software (<http://genecodis.cnb.csic.es/analysis>) ([@b20-or-40-02-0647]). P\<0.01 was set as the cut-off for selecting significantly enriched functional GO terms. KOBAS version 2.0 software (<http://kobas.cbi.pku.edu.cn>) was used to enrich the signaling pathways of DEGs ([@b21-or-40-02-0647]). P\<0.05 was set as the threshold for determining significantly enriched pathways.

### Protein-protein interaction network (PPI)

In order to elucidate the protein interactions between upregulated and downregulated DEGs in HPSCC, the BioGRID database was used to screen pairs of interacting proteins ([@b22-or-40-02-0647]). The PPI network was visualized using Cytoscape (<http://cytoscape.org/>) ([@b23-or-40-02-0647]). In the network, nodes represent proteins and edges represent interaction between two proteins.

### Validation of the expression of selected DEGs in The Cancer Genome Atlas (TCGA)

TCGA dataset was used to validate the expression of selected DEGs in HPSCC patients with a large sample size by using the online software SurvExpress (<http://bioinformatica.mty>. itesm.mx:8080/Biomatec/SurvivaX.jsp).

Results
=======

### RNA sequencing of HPSCC specimens

Total RNA was extracted from HPSCC tissues and adjacent normal controls from 3 patients. A total of 5 out of 6 samples, including 1C, 1N, 3C, 3N and 2C passed the assessment for RNA quality and quantity. Sample 2N did not pass the assessment, as the RIN value was not applicable ([Table II](#tII-or-40-02-0647){ref-type="table"}). A total of 5 samples were used for library construction and RNA-sequencing. For each sample, RNA-sequencing reads were generated and yielded 34--44 million sequencing reads per sample ([Table III](#tIII-or-40-02-0647){ref-type="table"}). All sequencing reads were aligned to the human hg19 genome by using TopHat and FPKM and the relative expression of genes was determined using the Cufflinks tool.

### DEGs and differentially expressed miRNAs between primary HPSCC and adjacent normal controls

A total of 160 DEGs, including 16 upregulated and 144 downregulated genes, were identified in the HPSCC tumors compared to the adjacent normal controls using the screening criteria FDR\<0.05 and abs (log~2~FC) \>1 (data not shown). In addition, a total of 79 differentially expressed miRNAs (48 upregulated and 31 downregulated miRNAs) were identified in the HPSCC tumors compared to adjacent normal controls using the screening criteria P\<0.001 and abs (log~2~FC) \>2 (data not shown).

As shown in [Table IV](#tIV-or-40-02-0647){ref-type="table"}, zinc activated ion channel (*ZACN*), chorionic gonadotropin β subunit 3 (*CGB3*) and zinc finger protein 385C (*ZNF385C*) were the top 3 upregulated genes. Ribosomal protein L26 (*RPL26*), ribosomal protein S6 (*RPS6*) and S-phase kinase associated protein 1 (*SKP1*) were the top 3 downregulated genes in HPSCC. The expression pattern of the top 20 upregulated and downregulated DEGs was examined by two-way hierarchical clustering analysis ([Fig. 1](#f1-or-40-02-0647){ref-type="fig"}). Compared to the normal control, metastasis-associated lung adenocarcinoma transcript 1 (*MALAT1*) was a significantly downregulated long non-coding RNA in HPSCC based on our RNA-sequencing data (FDR=0.014705). The top 20 differentially expressed miRNAs are shown in [Table V](#tV-or-40-02-0647){ref-type="table"}. As shown in [Table V](#tV-or-40-02-0647){ref-type="table"}, hsa-let-7i-5p, hsa-miR-136-5p and hsa-miR-143-5p were the top 3 upregulated miRNAs in HPSCC, and hsa-miR-15a-5p, hsa-miR-2278 and hsa-miR-125a-5p were the top 3 downregulated miRNAs in HPSCC.

### miRNA target gene interactions

Following target correlation analysis, a total of 339 miRNA-target pairs were obtained in HPSCC. A total of 228 upregulated miRNA-target pairs and 9 downregulated miRNA-target pairs were predicted using 6 prediction tools. A total of 101 upregulated miRNAs-target pairs and 1 downregulated miRNAs-target pair were validated in the miRWalk dataset. The top 10 miRNAs that targeted the majority of genes are listed in [Table VI](#tVI-or-40-02-0647){ref-type="table"}. The miRNA-target network between DEGs and differentially expressed miRNAs is presented in [Fig. 2](#f2-or-40-02-0647){ref-type="fig"}.

### Functional annotation of DEGs

GO annotation of the 160 identified DEGs in HPSCC was performed to elucidate the biological roles of DEGs using the GeneCodis 3 online software. P\<0.05 was used to determine significantly enriched GO terms. The most enriched 'molecular functions' of the DEGs were carbon-sulfur lyase activity (GO, 0016846), phosphotransferase activity, for other substituted phosphate groups (GO, 0016780) and CDP-alcohol phosphatidyltransferase activity (GO, 0017169). The most enriched 'cellular components' were intracellular organelle part (GO, 0044446), organelle part (GO, 0044422) and cytoplasm (GO, 0005737). The most enriched 'biological processes' were mRNA metabolic process (GO, 0016071), RNA processing (GO, 0006396) and RNA splicing (GO, 0008380) ([Figs. 3](#f3-or-40-02-0647){ref-type="fig"}--[5](#f5-or-40-02-0647){ref-type="fig"}).

### KEGG pathway enrichment

We performed KEGG pathway enrichment analysis for DEGs using KOBAS version 2.0. P\<0.05 was used as the criteria for pathway enrichment. The most enriched pathways were spliceosome (hsa03040), cell cycle (hsa04110) and RNA degradation (hsa03018) ([Fig. 6](#f6-or-40-02-0647){ref-type="fig"}).

### PPI network of DEGs in primary HPSCC compared to adjacent normal controls

PPI networks of the top 20 upregulated and downregulated DEGs in HPSCC compared to adjacent normal controls were determined using Cytoscape, which consisted of 673 nodes and 812 edges (data not shown). The proteins that had high connectivity with other proteins were hub proteins. In the PPI network, SKP1, NONO and ZACN were the hub proteins, which interacted with 166, 101 and 70 proteins, respectively ([Fig. 7](#f7-or-40-02-0647){ref-type="fig"}).

### Expression validation of selected DEGs in TCGA

A total of 5 DEGs \[*SKP1, ZACN, NONO*, cold shock domain containing E1 (*CSDE1*), chorionic gonadotropin β subunit 3 (*CGB3*) and *MALAT1*\] were selected to perform the tumor risk evaluation in HPSCC by using the head and neck squamous cell carcinoma datasets (283 samples) in TCGA. *CGB3, SKP1* and *ZACN* were upregulated while *MALAT1, NONO* and *CSDE1* were downregulated in the HPSCC high-risk group ([Fig. 8](#f8-or-40-02-0647){ref-type="fig"}). Additionally, we also performed validation of *SKP1, NONO* and *MALAT1* using the HPSCC dataset in TCGA. The result showed that the expression of *SKP1, NONO* and *MALAT1* was decreased in HPSCC tissues compared to the normal control, which was consistent with the RNA-sequencing analysis ([Fig. 9](#f9-or-40-02-0647){ref-type="fig"}).

Discussion
==========

At present, there is a lack of early detection biomarkers in clinical practice for HPSCC. To the best our knowledge, this is the first study to report the expression pattern of mRNAs and miRNAs in HPSCC via high-throughput RNA sequencing.

*SKP1* was significantly downregulated in HPSCC compared to adjacent normal controls ([Table IV](#tIV-or-40-02-0647){ref-type="table"}). SKP1 had the highest connectivity with 193 proteins ([Fig. 7](#f7-or-40-02-0647){ref-type="fig"}). According to KEGG signaling pathway enrichment, *SKP1* was significantly enriched in cell cycle and circadian rhythm. In *homo sapiens, SKP1* encodes S-phase kinase-associated protein 1, which is a scaffold protein of the ubiquitin E3 ligase Skp1/Cullin1/Rbx1/F-box protein complex (SCF complex). The SCF complex catalyzes the ubiquitination of proteins, which are involved in cell-cycle progression, signal transduction and transcription ([@b24-or-40-02-0647]). *SKP1* was overexpressed in 56.3% of the non-small cell lung cancer (NSCLC) specimens and elevated *SKP1* was associated with a poor prognosis ([@b25-or-40-02-0647]). The other component of the SCF complex, cullin, is highly expressed in NSCLC tissues and significantly associated with histological differentiation and clinical stage ([@b26-or-40-02-0647]). Our finding indicated that *SKP1* may play vital roles in the development of HSPCC, which indicates that it may serve as a diagnostic and prognostic biomarker for HSPCC.

Apart from SKP1, ZACN (also termed L2, ZAC) was also a hub protein according to the HSPCC-specific PPI network. *ZACN* is located at chromosome 17, and it encodes zinc-activated ion channel, which belongs to the cysteine-loop superfamily of ligand-gated ion channels. *ZACN* mRNA is expressed in various organs and tissues, including the brain, pancreas, liver, lung, heart, kidney and skeletal muscle ([@b27-or-40-02-0647]). The overexpression of *ZACN* was implicated in transient neonatal diabetes mellitus, which is a rare inherited diabetic syndrome apparent in neonate and again during early adulthood. In a transgenic mouse model, the expression of human *ZACN* and hydatidiform mole associated and imprinted (*HYMAI*) impaired the development of the endocrine pancreas and the function of β cells ([@b28-or-40-02-0647]). In the present study, *ZACN* was the most significantly upregulated gene in the HPSCC dataset compared to the adjacent normal control. The overexpression of *ZACN* in HPSCC was first reported in this study. The biological roles of *ZACN* overexpression in HPSCC warrant further investigation in *in vitro* and *in vivo* studies.

*NONO* encodes an RNA-binding protein and functions to regulate transcription and RNA splicing in the nucleus. *NONO* has been implicated in the progression of various tumor types, including breast and colorectal cancer and melanoma. *NONO* was also reported to regulate lipid metabolism by binding to SREBP-1A in breast cancer ([@b29-or-40-02-0647]).

Gastric adenocarcinoma associated, positive CD44 regulator, long intergenic non-coding RNA (*GAPLINC*) promotes cell invasion by targeting snail family transcriptional repressor 2 (*SNAI2*) via binding with *NONO* in colorectal cancer ([@b30-or-40-02-0647]). As a hub protein of the HSPCC-specific PPI network, *NONO* was significantly downregulated in HPSCC in this study. In addition, *NONO* was targeted by hsa-miR-29b-2-5p ([Table VI](#tVI-or-40-02-0647){ref-type="table"}). It has been reported that miR-29b-2-5p was potentially associated with survival in high-grade serous ovarian carcinoma ([@b31-or-40-02-0647]). Furthermore, miR-29b-2-5p has been shown to be downregulated in gallbladder cancer ([@b32-or-40-02-0647]). It was suggested that *NONO* may be involved in HPSCC under the regulation of hsa-miR-29b-2-5p.

*CGB3* is a member of the glycoprotein hormone β chain family and encodes the β 3 subunit of chorionic gonadotropin ([@b33-or-40-02-0647]). Previous studies have indicated that the overexpression of *CGB3* plays a role in carcinogenesis ([@b34-or-40-02-0647],[@b35-or-40-02-0647]). The synthesis of human chorionic gonadotropin β subunit has been detected in 30--50% of various malignant tumors ([@b36-or-40-02-0647],[@b37-or-40-02-0647]). In addition, upregulated *CGB3* has been found to be closely associated with the metastatic cancer phenotype, resistance to therapy, as well as with a poor prognosis ([@b37-or-40-02-0647],[@b38-or-40-02-0647]). To date, to the best of our knowledge, no study has reported the association between *CGB3* and HSPCC. In the present study, an increased *CGB3* expression was detected in patients with HSPCC. Hence, it can be concluded that *CGB3* may be involved in the pathogenesis of HSPCC; however, its precise function warrants further investigation.

*MALAT1* was the first long non-coding RNA prognostic biomarker identified for early-stage NSCLC ([@b39-or-40-02-0647]). The deregulation of *MALAT1* has been found in various types of cancer, including lung, breast, pancreas, colon, prostate and liver cancer ([@b40-or-40-02-0647]). Previous studies have demonstrated that *MALAT1* plays a role in cell proliferation, invasion and tumorigenesis ([@b41-or-40-02-0647]--[@b43-or-40-02-0647]). In addition, the prognostic value of *MALAT1* for cancer metastasis of cancer has been reported ([@b44-or-40-02-0647]). The expression of *MALAT1* was significantly downregulated in HSPCC in this study, which suggested that *MALAT1* may be a key regulator of tumorigenesis in HSPCC. In addition, long-term studies are required in order to identify whether *MALAT1* is a predictor for metastasis of HSPCC.

*CSDE1* (also known as UNR) encodes the RNA-binding protein, which is found to be upregulated in melanoma tumors, and promotes invasion and metastasis ([@b45-or-40-02-0647]). The upregulation of *CSDE1* has also been identified in breast cancer ([@b46-or-40-02-0647]), which suggests that *CSDE1* may be involved in tumorigenesis. In the present study, the expression of *CSDE1* was downregulated in HSPCC, which may be due to the difference in the type of cancer tissues used. Additionally, this study demonstrated that *CSDE1* is under the regulation of hsa-miR-497-5p and hsa-miR-125b-5p ([Table VI](#tVI-or-40-02-0647){ref-type="table"}). The expression of hsa-miR-497-5p has been reported to be significantly decreased in triple-negative breast cancer ([@b47-or-40-02-0647]) and to be negatively associated with survival in oropharyngeal squamous cell carcinoma ([@b48-or-40-02-0647]). hsa-miR-125b-5p is involved in regulating the proliferation, migration and invasion of tumor cells. The overexpression of hsa-miR-125b-5p has been shown to inhibit cell proliferation, migration and invasion in esophageal squamous cell carcinoma ([@b49-or-40-02-0647]). The underlying molecular mechanism of *CSDE1* under the regulation of hsa-miR-497-5p and hsa-miR-125b-5p in HPSCC need to be elaborated in future studies.

In differentially expressed miRNAs, we observed that hsa-let-7i-5p, hsa-miR-136-5p and hsa-miR-143-5p were the top 3 upregulated miRNAs in HPSCC. hsa-miR-15a-5p, hsa-miR-2278 and hsa-miR-125a-5p were the top 3 downregulated miRNAs in HPSCC. hsa-let-7i-5p has been shown to be upregulated in triple-negative breast cancer cells, colon cancer cells and non-muscle invasive bladder cancer cells ([@b50-or-40-02-0647]--[@b52-or-40-02-0647]). The upregulation of hsa-let-7i-5p is associated with an advanced stage, a high grade and therefore, with the progression of clear cell renal cell carcinoma ([@b53-or-40-02-0647]). hsa-miR-136-5p has been shown to be significantly upregulated in osteosarcoma and colorectal adenocarcinoma ([@b54-or-40-02-0647],[@b55-or-40-02-0647]). hsa-miR-143-5p acts as a strong tumor suppressive factor. It has been confirmed that hsa-miR-143-5p inhibits the proliferation, invasion and migration of cervical cancer cells ([@b56-or-40-02-0647]). It has also been shown that hsa-miR-15a-5p acted as a tumor suppressor by silencing the expression of growth promoting oncogenes ([@b57-or-40-02-0647]--[@b59-or-40-02-0647]). In chronic myeloid leukemia, hsa-miR-15a-5p has been shown to suppress cell growth and metastasis ([@b60-or-40-02-0647]). In addition, hsa-miR-15a-5p has been shown to be associated with patient survival in lung adenocarcinoma ([@b61-or-40-02-0647]). hsa-miR-2278 has been shown to be associated with survival in both rectal and colon cancer ([@b62-or-40-02-0647]). hsa-miR-125a-5p is known to act as a tumor suppressor and is downregulated in various malignant tumors, such as laryngeal carcinoma and verrucous carcinoma of the head and neck ([@b63-or-40-02-0647],[@b64-or-40-02-0647]). In multiple myeloma cells, the inhibition of hsa-miR-125a-5p has been shown to reduce cell growth, increased cell apoptosis and attenuated cell migration ([@b65-or-40-02-0647]). On the whole, these differentially expressed miRNAs may play an important role in the development of HPSCC. In the present study, spliceosome, cell cycle and RNA degradation were significantly enriched signal pathways in HPSCC. Deregulated genes regulated the progression and development of cancer via the cell cycle in various cancer types, including lung adenocarcinoma, colorectal and head and neck cancer ([@b44-or-40-02-0647]--[@b46-or-40-02-0647]), which indicated that the cell cycle pathway was implicated in the tumorigenesis of HPSCC.

In conclusion, in the present study, we identified 160 DEGs and 79 differentially expressed miRNAs in HPSCC tissues compared to adjacent normal tissues. The top 20 upregulated and downregulated genes in HPSCC were used to construct PPI networks, where SKP1, NONO and ZACN were the hub proteins. DEGs were significantly enriched in the spliceosome, cell cycle and RNA degradation. The present study was the first to investigate the gene and mRNA expression profiles in HPSCC. Our findings may provide the groundwork for the identification of early diagnosis biomarkers for HPSCC and the mechanisms that underlie its pathogenesis, as well as make a contribution for future drug design. However, there are limitations to this study. Firstly, the sample size in the RNA-sequencing was small. Therefore, large numbers of HPSCC tumor samples are needed for further research. Secondly, although deregulated genes, miRNAs and pathways in HPSCC were identified, the biological functions of these genes, miRNAs and pathways were not investigated in this study. *In vitro* and *in vivo* experiments are essential for the elucidation of the biological roles of DEGs and differentially expressed miRNAs in HPSCC in future investigations.
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![Tumor risk evaluations of *SKP1, ZACN, NONO, CSDE1, CGB3* and *MALAT1* in the TCGA dataset. CGB3, chorionic gonadotropin beta subunit 3; CSDE1, cold shock domain containing E1; MALAT1, metastasis associated in lung adenocarcinoma transcript 1; NONO, non-POU domain containing octamer binding; SKP1, S-phase kinase associated protein 1; TCGA, The Cancer Genome Atlas; ZACN, zinc activated ion channel.](OR-40-02-0647-g07){#f8-or-40-02-0647}

![Box plots of *SKP1, NONO* and *MALAT1* in the TCGA dataset. MALAT1, metastasis associated in lung adenocarcinoma transcript 1; NONO, non-POU domain containing octamer binding; SKP1, S-phase kinase associated protein 1; TCGA, The Cancer Genome Atlas.](OR-40-02-0647-g08){#f9-or-40-02-0647}

###### 

Basic characteristics of patients with HPSCC.

  Patient ID   Age (years)   Sex    Cigarettes per day   Years of smoking   Alcohol consumption each day (g)   Years of alcohol consumption   TNM stage   Histological feature   Tumor grade
  ------------ ------------- ------ -------------------- ------------------ ---------------------------------- ------------------------------ ----------- ---------------------- -------------
  1            62            Male   20                   40                 100                                30                             T2N1M0      SCC                    Medium
  2            56            Male   20                   30                 250                                30                             T2N1M0      SCC                    Medium
  3            64            Male   20                   30                 No details                         No details                     T3N1M0      SCC                    Medium

HPSCC, hypopharyngeal squamous cell carcinoma.

###### 

RNA quantity and quality measurements of 6 samples.

  Sample ID   RNA volume (µl)   RNA concentration (ng/µl)   RNA amount (µg)   RIN
  ----------- ----------------- --------------------------- ----------------- -----
  1C          38                2,723                       103.47            4
  2C          65                2,692                       174.98            7.6
  3C          27                3,288                       88.78             7.5
  1N          14                334                         4.68              5.7
  2N          12                70                          0.84              N/A
  3N          38                1,784                       67.79             4.7

C, primary tissues of hypopharyngeal squamous cell carcinoma; N, adjacent normal tissues; RIN, RNA integrity number; N/A, not available.

###### 

RNA-sequencing of the specimens.

  Sample_ID   Total reads   Total bases   Q20%    Q30%    Average coverage
  ----------- ------------- ------------- ------- ------- ------------------
  1C          4.4×10^7^     5.6×10^9^     96.66   93.47   99.1863479139598
  2C          3.5×10^7^     4.3×10^9^     96.61   93.33   99.4073847620807
  3C          3.4×10^7^     4.2×10^9^     96.68   93.41   99.2552832336352
  1N          4.3×10^7^     5.4×10^9^     96.27   92.79   99.348671268904
  3N          3.5×10^7^     4.4×10^9^     96.58   93.32   99.2810150213976

C, primary tissues of hypopharyngeal squamous cell carcinoma; N, adjacent normal tissues; Q20, the percentage of bases with quality value \>20; Q30, the percentage of bases with quality value \>30.

###### 

DEGs in HPSCC.

  Gene ID               Gene symbol   Log2FC     P-value    FDR
  --------------------- ------------- ---------- ---------- ----------
  Upregulated genes                                         
    353174              *ZACN*        6.288149   8.86E-05   0.038292
        1082            *CGB3*        5.765826   4.12E-05   0.034011
    201181              *ZNF385C*     5.310858   0.000127   0.039757
    126567              *C2CD4C*      5.256596   0.000222   0.049962
    84696               *ABHD1*       5.10952    4.07E-05   0.034011
    6370                *CCL25*       5.035685   5.76E-05   0.035804
    693222              *MIR637*      4.830281   6.51E-05   0.035863
    692091              *SNORD23*     4.628719   3.74E-05   0.033502
    9075                *CLDN2*       4.580931   0.000195   0.047531
    6082                *SNORD20*     4.49704    8.54E-05   0.038072
    284339              *TMEM145*     4.395233   8.36E-05   0.038072
    2251                *FGF6*        3.962287   6.55E-05   0.035863
    136371              *ASB10*       3.961177   0.000138   0.040535
    248                 *ALPI*        3.959662   7.79E-05   0.038041
    54964               *C1orf56*     3.849454   0.000166   0.044327
    84939               *MUM1*        3.145926   9.19E-05   0.038292
  Downregulated genes                                       
    6154                *RPL26*       −10.6837   1.06E-06   0.014705
    6194                *RPS6*        −9.89489   1.14E-06   0.014705
    6500                *SKP1*        −7.78013   3.26E-06   0.030707
    8531                *YBX3*        −7.37473   2.26E-05   0.033502
    347                 *APOD*        −7.36529   6.56E-06   0.033502
    51614               *ERGIC3*      −7.28305   0.000122   0.03936
    4501                *MT1X*        −6.78769   0.000215   0.049189
    3486                *IGFBP3*      −6.56019   6.70E-06   0.033502
    7812                *CSDE1*       −6.49789   5.73E-06   0.033502
    4841                *NONO*        −6.45686   8.40E-06   0.033502
    6317                *SERPINB3*    −6.45555   0.000213   0.049086
    5360                *PLTP*        −6.29414   2.00E-05   0.033502
    1528                *CYB5A*       −6.28125   2.21E-05   0.033502
    51596               *CUTA*        −6.24975   0.000199   0.048247
    57035               *RSRP1*       −6.20271   0.000205   0.048326
    7385                *UQCRC2*      −6.01731   8.71E-06   0.033502
    1639                *DCTN1*       −5.79807   0.000143   0.040725
    1212                *CLTB*        −5.70891   0.000204   0.048326
    5589                *PRKCSH*      −5.58244   8.30E-05   0.038072
    6194                *RPS6*        −9.89489   1.14E-06   0.014705
    340277              *FAM221A*     −3.26588   1.30635    −17.5303

DEGs, differentially expressed genes; HPSCC, hypopharyngeal squamous cell carcinoma; FDR, false discovery rate.

###### 

Top 20 differentially expressed miRNAs in HPSCC.

  miRNA symbol           Log2FC         P-value
  ---------------------- -------------- -----------
  Upregulated miRNAs                    
    hsa-let-7i-5p        2.122547495    0
    hsa-miR-136-5p       2.444466751    0
    hsa-miR-143-5p       2.976688335    0
    hsa-miR-370-3p       3.344940583    0
    hsa-miR-140-3p       3.395556571    0
    hsa-let-7g-5p        9.933859336    8.71E-85
    hsa-miR-106b-3p      9.933859336    8.71E-85
    hsa-miR-127-3p       9.933859336    8.71E-85
    hsa-miR-148b-3p      9.933859336    8.71E-85
    hsa-miR-187-3p       9.933859336    8.71E-85
  Downregulated miRNAs                  
    hsa-miR-15a-5p       −12.79407766   0
    hsa-miR-2278         −12.05711064   1.56E-243
    hsa-miR-125a-5p      −10.472141     3.27E-107
    hsa-miR-1269a        −10.472141     3.27E-107
    hsa-miR-135b-5p      −10.472141     3.27E-107
    hsa-miR-18a-3p       −10.472141     3.27E-107
    hsa-miR-19b-3p       −10.472141     3.27E-107
    hsa-miR-200b-3p      −10.472141     3.27E-107
    hsa-miR-203b-3p      −10.472141     3.27E-107
    hsa-miR-20a-5p       −10.472141     3.27E-107

HPSCC, hypopharyngeal squamous cell carcinoma.

###### 

Top 10 miRNAs that targeted the majority of genes.

  miRNA                Up/downregulated   Count of targets   Target genes
  -------------------- ------------------ ------------------ ---------------------------------------------------------------------------------------------------------------------
    hsa-miR-193b-3p    Upregulated        18                 CDK9, HNRNPUL1, ELK3, ACOT9, GLO1, HPRT1, IRF1, MCM3, NONO, SCLY, RPL26, YBX3, CTSC, ERC1, MDM2, CSDE1,CGNL1, BCAR1
    hsa-miR-214-3p     Upregulated        17                 ERC1, CDK9, SYNPO, NUDT16, DCTN1, CLASP1, ZDHHC8, APOD, INCENP, MYO1E, BIK, TRA2B, TFAM, ITCH, CGNL1, MPZL1, JAG1
    hsa-miR-497-5p     Upregulated        14                 RBBP6, YWHAH, CDS1, CTSC, SYNPO, NUDT16, INCENP, IRF1, CSDE1, PPP1R14C, CGNL1, MPZL1, MTSS1, CDC42SE2
    hsa-miR-29b-2-5p   Upregulated        13                 TMEM18, NUDT16, CPM, CPT1A, ERC1, C2CD3, NFYB, NONO, CXorf40B, LEPROT, TFAM, CGNL1, CTSC
    hsa-miR-125b-5p    Upregulated        12                 EXOC7, LSM4, PIGF, SYNPO, DCTN1, ZDHHC8, IGFBP3, IRF1, NADK, CSDE1, ITCH, MPZL1
    hsa-miR-3150b-3p   Upregulated        12                 KAT7, NUDT16, CPM, ERC1, HCCS, NFYB, CRLS1, LEPROT, PRPSAP2, CDC42SE2, SOD3, TULP3
    hsa-miR-185-5p     Upregulated        11                 KAT7, INCENP, MDM2, NUDT16, CPM, CPT1A, ERC1, HCCS, LEPROT, PPP1R14C, MPZL1
    hsa-miR-342-3p     Upregulated        11                 DARS, ERC1, ACOT9, LETMD1, PRKCSH RPL26, NUDT16, ZDHHC8, CGNL1, MPZL1
    hsa-miR-378a-5p    Upregulated        11                 IRF1, RPS6, CTSC, CPM, CPT1A, ERC1, ANKLE2, FTSJ2, NFYB, TULP3, ITCH
    hsa-miR-629-3p     Upregulated        11                 HNRNPUL1, ACOT9, TRIB1, CDK9, CTSC, NUDT16, CPM, CPT1A, ERC1, SRP54, TFAM
